HomeCompareSONN vs YUM

SONN vs YUM: Dividend Comparison 2026

SONN yields 158.73% · YUM yields 1.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SONN wins by $33.32M in total portfolio value
10 years
SONN
SONN
● Live price
158.73%
Share price
$1.26
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$33.43M
Annual income
$14,929,974.02
Full SONN calculator →
YUM
YUM
● Live price
1.86%
Share price
$154.59
Annual div
$2.88
5Y div CAGR
51.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$107.9K
Annual income
$40,443.52
Full YUM calculator →

Portfolio growth — SONN vs YUM

📍 SONN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSONNYUM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SONN + YUM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SONN pays
YUM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SONN
Annual income on $10K today (after 15% tax)
$13,492.06/yr
After 10yr DRIP, annual income (after tax)
$12,690,477.92/yr
YUM
Annual income on $10K today (after 15% tax)
$158.35/yr
After 10yr DRIP, annual income (after tax)
$34,376.99/yr
At 15% tax rate, SONN beats the other by $12,656,100.92/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SONN + YUM for your $10,000?

SONN: 50%YUM: 50%
100% YUM50/50100% SONN
Portfolio after 10yr
$16.77M
Annual income
$7,485,208.77/yr
Blended yield
44.63%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on YUM right now

SONN
Analyst Ratings
4
Buy
Consensus: Buy
Altman Z
-14.0
Piotroski
3/9
YUM
Analyst Ratings
18
Buy
30
Hold
3
Sell
Consensus: Hold
Price Target
$173.15
+12.0% upside vs current
Range: $158.00 — $190.00
Altman Z
2.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SONN buys
0
YUM buys
0
No recent congressional trades found for SONN or YUM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSONNYUM
Forward yield158.73%1.86%
Annual dividend / share$2.00$2.88
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.4%
Portfolio after 10y$33.43M$107.9K
Annual income after 10y$14,929,974.02$40,443.52
Total dividends collected$31.06M$81.2K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyHold

Year-by-year: SONN vs YUM ($10,000, DRIP)

YearSONN PortfolioSONN Income/yrYUM PortfolioYUM Income/yrGap
1← crossover$26,573$15,873.02$10,982$282.06+$15.6KSONN
2$67,853$39,419.99$12,189$438.29+$55.7KSONN
3$166,675$94,072.29$13,731$688.32+$152.9KSONN
4$394,305$215,962.78$15,789$1,097.12+$378.5KSONN
5$899,388$477,481.77$18,679$1,785.08+$880.7KSONN
6$1,980,205$1,017,859.40$22,975$2,988.18+$1.96MSONN
7$4,213,254$2,094,435.11$29,784$5,200.49+$4.18MSONN
8$8,672,949$4,164,766.74$41,408$9,539.16+$8.63MSONN
9$17,292,333$8,012,278.11$63,071$18,765.27+$17.23MSONN
10$33,432,771$14,929,974.02$107,930$40,443.52+$33.32MSONN

SONN vs YUM: Complete Analysis 2026

SONNStock

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.

Full SONN Calculator →

YUMConsumer Discretionary

YUM! Brands, Inc., together with its subsidiaries, develops, operates, and franchises quick service restaurants worldwide. It operates through four segments: the KFC Division, the Taco Bell Division, the Pizza Hut Division, and the Habit Burger Grill Division. The company operates restaurants under the KFC, Pizza Hut, Taco Bell, and The Habit Burger Grill brands, which specialize in chicken, pizza, made-to-order chargrilled burgers, sandwiches, Mexican-style food categories, and other food products. As of December 31, 2021, it had 26,934 KFC units; 18,381 Pizza Hut units; 7,791 Taco Bell units; and 318 The Habit Burger Grill units in approximately 157 countries and territories. The company was formerly known as TRICON Global Restaurants, Inc. and changed its name to YUM! Brands, Inc. in May 2002. YUM! Brands, Inc. was incorporated in 1997 and is headquartered in Louisville, Kentucky.

Full YUM Calculator →
📬

Get this SONN vs YUM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SONN vs SCHDSONN vs JEPISONN vs OSONN vs KOSONN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.